TY - JOUR T1 - Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma JF - Br J Haematol Y1 - 2002 A1 - Au,W. Y. A1 - Chan,E. C. A1 - Siu,L. L. A1 - Lau,T. C. A1 - Lie,A. K. A1 - Ma,S. K. A1 - Kwong,Y. L. KW - Acute Disease KW - Bone Marrow Transplantation / *adverse effects KW - Carcinoma, Bronchogenic / complications KW - Fatal Outcome KW - Female KW - Humans KW - Leukemia, Myeloid / *etiology / genetics KW - Leukemia, Myeloid, Philadelphia-Positive / therapy KW - Lung Neoplasms / complications KW - Male KW - Middle Aged KW - Pedigree KW - Recurrence KW - Research Support, Non-U.S. Gov't KW - Smoking / adverse effects KW - Tissue Donors KW - Transplantation, Homologous AB - Donor-derived leukaemia is exceptional after allogeneic bone marrow transplantation (BMT). A woman with chronic myeloid leukaemia received an allogeneic BMT from a human leucocyte antigen-identical brother. The donor, a 50-year-old non-smoker, died of squamous cell bronchogenic carcinoma 1 year later. At 4 years post BMT, the patient became BCR/ABL positive and relapsed with acute myeloid leukaemia, which was shown to be donor-derived cytogenetically and molecularly. Retrospective analysis showed that the donor-leukaemic clone had started to evolve as early as 6 months post BMT. Sequencing of p53 ruled out Li-Fraumeni syndrome. Predisposition to malignancy might be an underlying mechanism of donor-cell leukaemia. VL - 119 CP - 3 N1 - 0007-1048 (Print) Case Reports Journal Article ID - 99 ER -